KCCure is the only organization to provide private peer reviewed kidney cancer research grants.
A core feature of our mission is to engage leaders in the provider community and the patient community to identify kidney cancer research priorities and ensure that research grant funding is geared toward filling those gaps.
KCCure Kidney Cancer Scientific Advisory Board
Our scientific advisory board is made up of the top leaders in the field of kidney cancer research; including leaders from both of the NCI designated Kidney Cancer Specialized Programs of Research Excellence (Spore), leaders in the field of medical oncology, urological oncology, pathology, basic research and pyscho-oncology.
KCCure Kidney Cancer Patient Advisory Board
Our patient advisory board is comprised of leaders in the kidney cancer patient advocacy community who represent rare subtypes of kidney cancer, including renal medullary carcinoma, translocation carcinoma, and papillary carcinoma, as well as those representing patients from different locations and demographics. KCCure advisory board members can be found representing patients throughout the country on a variety of boards including: the Patient-Centered Outcomes Research Institute (PCORI) ambassador program, the Alliance Cooperative Group, the Southwest Oncology Cooperative Group, the NCI GU Steering Committee, the Society for Immunotherapy Renal Cell Guidelines Panel, and the CDMRP Kidney Cancer Research Program Programmatic Panel.
KCCure Kidney Cancer Research Process
All grant proposals go through a rigorous peer review process aimed at identifying the best and most promising research that will provide the greatest opportunity to advance the understanding of kidney cancer and improve management and treatment of the disease.
KCCure Innovation Awards
In 2017, KCCure announced the Kidney Cancer Innovation Research Grant Award of $100,000 offered over two years for a pilot project focused on cutting edge, innovative scientific research in kidney cancer.
Applicants for this award are encouraged to focus on a new research direction, explore innovative ideas, test unconventional, but potentially important hypotheses, or ascertain the feasibility of new research approaches. The application period for the 2018 award is now closed.
2018 Innovation Award Winner – Qing Zhang, MD, PhD, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill. TBK1 Serves as a Novel Therapeutic Target in Kidney Cancer with VHL Loss.
For more information:
Information about new awards will be updated here as RFPs are released. If you’re a researcher and you’d like to discuss funding opportunities with KCCure, contact us at email@example.com.